Related Experiment Video

Updated: Jun 6, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic

Michele Guida1, Antonio Cramarossa, Ettore Fistola

  • 1Department of Medical Oncology; National Institute of Cancer, Bari, Italy. micguida@libero.it

Journal of Translational Medicine
|November 12, 2010
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: Jun 6, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Cemiplimab in cutaneous squamous cell carcinoma: a longer follow-up study focusing on the late toxicities.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026

Clinical impact and therapeutic potential of tertiary lymphoid structures in melanoma.

Frontiers in immunology·2026

Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Enhancing Recovery After Endoscopic Carpal Tunnel Release: The Role of Neurotrophic Supplementation.

Plastic and reconstructive surgery. Global open·2026

Adjuvant immunotherapy in high-risk stage II melanoma: real-world outcomes from a large multicenter retrospective study.

Cancer immunology, immunotherapy : CII·2026

Case Report: Long-term maternal and neonatal outcomes after nivolumab therapy in metastatic tonsillar sarcomatoid squamous cell carcinoma.

Frontiers in immunology·2026

FAP-targeted ROS-responsive nanoparticles delivering siBTF3 modulate the TME to enhance immunotherapy in colorectal cancer.

Journal of translational medicine·2026

Tet2 deficiency drives age-related heterogeneous progression of myeloid neoplasms through epigenetic-immune microenvironment imbalance.

Journal of translational medicine·2026

Three-dimensional spheroid models in breast cancer: tumor microenvironment complexity, cancer stem cell-driven resistance, and translational model integration.

Journal of translational medicine·2026

EV-transferred miR-7111-3p inhibits malignant phenotypes and tumor growth in nasopharyngeal carcinoma via targeting APP-regulated epithelial-mesenchymal transition.

Journal of translational medicine·2026

Computational identification and experimental validation of shared diagnostic biomarkers and gene signatures across HLA-B27-associated immune-mediated diseases.

Journal of translational medicine·2026

Enhancer-mediated DDIT4 activation by SMYD2-dependent H3K4me1 promotes pazopanib resistance in clear cell renal cell carcinoma.

Journal of translational medicine·2026

Paclitaxel induces NM2-dependent cellular contraction through GEF-H1 dissociation from microtubules and RhoA/ROCK activation in cancer cells.

Molecular oncology·2026

Renal function and urinary tubular biomarker abnormalities in untreated and entecavir- or tenofovir disoproxil fumarate-treated patients with chronic hepatitis B: a retrospective cross-sectional study.

Frontiers in medicine·2026

A Latent profile and network intervention analysis of psychosomatic symptoms in lung cancer immunotherapy patients.

PloS one·2026

Cannabis Use by Veterans and Potential Interactions With Antineoplastic Agents: Analysis and Literature Review.

Federal practitioner : for the health care professionals of the VA, DoD, and PHS·2026

Combined treatment of benznidazole with an electrolyzed oxidizing water against Trypanosoma cruzi on immunological and anatomopathological features in a murine model of Chagas disease.

Frontiers in immunology·2026

Outcome of Ceftazidime/Avibactam Versus Alternative Antibiotics for Treatment of Carbapenem-Resistant Enterobacterales Bacteremia in Patients With Hematologic Malignancies.

Journal of Korean medical science·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us